Hikma Pharmaceuticals Acquires Custopharm from Water Street Healthcare Partners

Hikma Pharmaceuticals has agreed to acquire Custopharm Inc., a US-based generic sterile injectables company, from Water Street Healthcare Partners for an initial $375 million plus up to $50 million in contingent consideration. The acquisition adds Custopharm's 13 approved products, R&D capabilities and pipeline to Hikma's injectables franchise and is expected to be accretive to Hikma's Injectables operating margin.